Advertisement
Advertisement
Chinese firms had enjoyed a privileged position because of the country’s regulatory system. Photo: Alamy
Pharma firms face shake-up with China’s plan to bulk-buy drugs
- Pilot programme involves major cities clubbing together to purchase certain medicines, driving down prices
- Chinese companies that have invested heavily in R&D stand best chance of survival
Topic |
Health in China
Updated: 4:41pm, 2 Jan, 2019
Advertisement
TOP PICKS
Chinese firms had enjoyed a privileged position because of the country’s regulatory system. Photo: Alamy
READ FULL ARTICLE
Advertisement
Advertisement
SCMP TODAY: INTL EDITION
Get updates direct to your inbox
By registering, you agree to our T&C and Privacy Policy
Thank you for your subscription.
You can also view our other newsletters.
Products & Services
Our Sites
DOWNLOAD THE SCMP APP
Copyright © 2019 South China Morning Post Publishers Ltd. All rights reserved.